SRR8942997
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- OXIDATIVE_PHOSPHORYLATION+0.460
- INTERFERON_GAMMA_RESPONSE+0.380
- TGF_BETA_SIGNALING+0.350
- PROTEIN_SECRETION+0.340
- WNT_BETA_CATENIN_SIGNALING+0.270
- HEME_METABOLISM+0.260
- P53_PATHWAY+0.210
- ADIPOGENESIS+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- CHOLESTEROL_HOMEOSTASIS-0.370
- MYC_TARGETS_V2-0.350
- APICAL_SURFACE-0.330
- MYOGENESIS-0.320
- TNFA_SIGNALING_VIA_NFKB-0.310
- MTORC1_SIGNALING-0.280
- ANGIOGENESIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202456 | — | — | 0.885 |
| 2 | SRR8943026 | — | — | 0.858 |
| 3 | TCGA-CF-A9FM-01A-11R-A38B-07 | — | — | 0.839 |
| 4 | SRR12202458 | — | — | 0.791 |
| 5 | SRR8942946 | — | — | 0.789 |
| 6 | SRR23303762 | — | — | 0.776 |
| 7 | DRR168515 | — | — | 0.771 |
| 8 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.748 |
| 9 | TCGA-E7-A678-01A-11R-A30C-07 | — | — | 0.735 |
| 10 | SRR26320087 | — | — | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |